Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated ISM4312A as a preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback